Welcome to our dedicated page for CONCENTRA GROUP HOLDINGS PAREN SEC filings (Ticker: CON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Concentra Group Holdings Parent, Inc. (NYSE: CON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a U.S. public issuer in the healthcare and occupational health services sector. Concentra files current reports on Form 8-K to communicate material events, including quarterly financial results, dividend declarations, share repurchase authorizations, and governance changes such as director appointments and executive equity awards.
Recent Form 8-K filings describe the company’s financial results for quarters ended June 30 and September 30, 2025, with accompanying press releases and presentations furnished as exhibits. These materials outline revenue performance, income from operations, patient visit metrics, and the expansion of Concentra’s network of occupational health centers and onsite health clinics. Other 8-K filings detail cash dividend declarations and the authorization of a share repurchase program, providing insight into the company’s capital allocation decisions.
Additional filings report governance-related events. For example, Concentra has filed 8-Ks regarding the appointment of new members to its Board of Directors and the grant of restricted stock to named executive officers under its equity incentive plan. These disclosures help investors understand changes in the company’s leadership and executive compensation structure. The company has also filed 8-Ks related to preliminary operational metrics and presentations at investor conferences.
Through Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain key points from documents such as Form 8-K and related exhibits. Real-time updates from the EDGAR system help ensure that new filings for CON are reflected promptly, while AI-generated highlights can assist in identifying important information about financial performance, dividends, share repurchases, and governance matters without reading every line of each filing.
Concentra Group Holdings Parent, Inc. reported an insider equity transaction by its Executive Vice President, Chief Digital & Data Officer. On 11/26/2025, the officer had 6,428 shares of common stock withheld at a price of $21.04 per share to cover tax obligations related to the vesting of restricted stock. After this tax withholding, the officer directly beneficially owns 113,572 shares of common stock. This type of transaction is administrative and does not represent an open-market purchase or sale.
Concentra Group Holdings Parent, Inc. reported an insider transaction by an executive officer. On 11/26/2025, the Executive Vice President, Chief Growth & Customer Officer had 5,903 shares of common stock withheld and disposed of at $21.04 per share to cover tax obligations from the vesting of restricted stock. After this tax withholding, the officer directly beneficially owned 114,097 shares of Concentra common stock.
Concentra Group Holdings Parent, Inc. executive shares were adjusted in connection with equity compensation. On 11/26/2025, an officer identified as the Executive Vice President and Chief Medical Officer reported a Form 4 transaction in the company’s common stock. A total of 6,540 shares of common stock were disposed of at $21.04 per share under transaction code F, which indicates shares were withheld to cover tax obligations arising from the vesting of restricted stock.
After this tax withholding event, the reporting person directly beneficially owned 113,460 shares of Concentra Group Holdings Parent, Inc. common stock. The filing reflects an administrative adjustment related to equity compensation rather than an open‑market purchase or sale.
Concentra Group Holdings Parent, Inc. (CON)11/25/2025, the reporting person made a bona fide gift of 100,000 shares of common stock, shown with transaction code G and a price of $0 per share, which reflects the nature of a gift rather than a sale.
After this transaction, the director directly held 5,433,794 shares of common stock. The report also lists additional indirect beneficial ownership through several family trusts, including 1,023,455 shares held by The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio and 1,032,115 shares held by the Robert A. Ortenzio Descendants Trust, plus three 2014 trusts each holding 226,286 shares for individual beneficiaries.
T. Rowe Price Associates, Inc. filed an Amendment No. 2 to Schedule 13G reporting a passive stake in Concentra Group Holdings Par (CON). The firm reports beneficial ownership of 17,166,753 shares of common stock, representing 13.4% of the class, with the Date of Event listed as 09/30/2025.
The filing shows sole voting power over 16,959,244 shares and sole dispositive power over 17,166,753 shares; there is no shared voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course and not to influence control. Within the reported holdings, T. Rowe Price Mid‑Cap Value Fund has an interest in 7,571,779 shares, or 5.9% of the class.
T. Rowe Price Investment Management, Inc. filed Amendment No. 1 to Schedule 13G reporting beneficial ownership of 6,267,949 shares of CONCENTRA GROUP HOLDINGS PAR common stock, representing 4.9% of the class as of 09/30/2025.
The firm reports sole voting power over 6,240,852 shares and sole dispositive power over 6,267,949 shares, with zero shared voting or dispositive power. The filing indicates the reporting person is an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Concentra Group Holdings Parent, Inc. (CON) disclosed new executive equity awards. On November 4, 2025, the Board’s Human Capital and Compensation Committee granted restricted shares to the company’s named executive officers under the 2024 Equity Incentive Plan. These restricted stock awards vest in equal installments on each of the first four anniversaries of the grant date.
Grants by executive:
- W. Keith Newton: 225,000 shares
- Matthew T. DiCanio: 180,000 shares
- John A. deLorimier: 60,000 shares
- John Anderson: 60,000 shares
- Michael Kosuth: 60,000 shares
- Su Zan Nelson: 60,000 shares
The awards are time-based and align compensation with multi-year service and performance horizons via four-year ratable vesting.
Concentra Group Holdings Parent, Inc. (CON) reported a Form 4 showing an equity award to an executive. On 11/04/2025, the officer received 40,000 shares of restricted stock at $0. The grant will vest in equal annual installments over four years. After this transaction, the reporting person beneficially owned 80,098 shares, held directly. The executive’s title is Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine.
Concentra Group Holdings Parent, Inc. (CON) reported an insider equity award. On 11/04/2025, a company officer received 60,000 shares of restricted stock at $0, increasing directly held common stock to 120,000 shares after the transaction. The award will vest in equal annual installments over four years.
The reporting person serves as Executive Vice President, Chief Operating Officer - East. This filing reflects a compensation grant rather than an open‑market purchase.
Concentra Group Holdings Parent, Inc. disclosed an officer equity award on Form 4. The President & Chief Financial Officer received 180,000 shares of restricted common stock on 11/04/2025 at a reported price of $0. The award will vest in equal annual installments over four years.
Following this grant, the officer’s beneficial ownership stands at 360,000 shares, held directly. This filing reflects routine executive equity compensation designed to align leadership with shareholders through multi‑year vesting.